Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1516915
This article is part of the Research Topic Research Advances toward One Health in Brucellosis View all 5 articles

Development and evaluation of the recombinant BP26 protein-based C-ELISA for human brucellosis diagnosis

Provisionally accepted
Yujia Xie Yujia Xie 1Shaoqing Lin Shaoqing Lin 2Liping Guo Liping Guo 1Xinru Qi Xinru Qi 1Shiqi Zhao Shiqi Zhao 1Qichuan Pei Qichuan Pei 1Yixiao Chen Yixiao Chen 1Qi Wu Qi Wu 1Yun Wang Yun Wang 3Meixue Yao Meixue Yao 1Dehui Yin Dehui Yin 1*
  • 1 Xuzhou Medical University, Xuzhou, China
  • 2 Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, China
  • 3 Huai'an Second People's Hospital, Huaian, China

The final, formatted version of the article will be published soon.

    Timely and accurate diagnosis is crucial for the effective treatment and prevention of brucellosis. Current serological diagnostics, primarily based on lipopolysaccharide (LPS), suffer from cross-reactivity with other Gram-negative bacteria, which limits their specificity. Periplasmic protein 26 (BP26), a highly immunogenic antigen found in Brucella, has emerged as a promising alternative for enhancing diagnostic specificity. This study aimed to develop and evaluate a competitive enzyme-linked immunosorbent assay (C-ELISA) utilizing monoclonal antibodies against BP26 for the diagnosis of human brucellosis, thereby providing a more accurate and specific diagnostic approach.The study produced monoclonal antibody (mAb) against the BP26 protein through traditional mouse hybridoma technology and developed the C-ELISA method, and compared with a C-ELISA method based on LPS mAb. The detection performance was validated through the analysis of 190 human serum samples, which included 95 brucellosis serum samples and 95 negative serum samples collected by the Xuzhou Center for Disease Control and Prevention, and a comparative analysis was conducted on the diagnostic efficacy of indirect ELISA for brucellosis using both BP26 and LPS-based methods.The BP26 mAb based C-ELISA achieved 100% sensitivity and specificity in detecting human brucellosis, significantly outperforming the C-ELISA based LPS mAb. Furthermore, the accuracy of the indirect enzyme-linked immunosorbent assay (I-ELISA) using BP26 protein was 98.95%, compared to an accuracy of LPS diagnosis was 99.47%. These results indicated that the BP26 mAb can effectively and accurately detected human brucellosis infections.This study successfully developed and evaluated a BP26 protein-based C-ELISA method for diagnosing human brucellosis, establishing a foundation for identifying alternative diagnostic antigens for brucellosis.

    Keywords: BP26 protein, Monoclonal antibody, Brucellosis, Competitive enzyme-linked immunosorbent assay, diagnosis

    Received: 25 Oct 2024; Accepted: 13 Dec 2024.

    Copyright: © 2024 Xie, Lin, Guo, Qi, Zhao, Pei, Chen, Wu, Wang, Yao and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dehui Yin, Xuzhou Medical University, Xuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.